Treadwell Therapeutics, Inc.

Treadwell Therapeutics, Inc. is a biotechnology startup founded in 2020 with the slogan "The Path to Better." The company focuses on developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities such as aneuploidy and immunogenicity. Its robust pipeline includes the lead candidate CFI-400945, a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials for cancers including TNBC, prostate cancer, and AML. Additionally, the company has other product candidates like CFI-402257, a clinical stage TTK inhibitor, and CFI-402411, a preclinical HPK1 inhibitor. In November 2021, Treadwell Therapeutics secured a noteworthy $91.00M Series B investment from a group of investors including Alpha Win Capital, Sino Biopharma, Prosperous Alliance Investments, 3W Fund Management, TIO Bioventures, Adrian Cheng, and Fortune Ocean Growth Fund. The company's efforts in developing innovative therapies and the substantial investment received demonstrate its potential in the biotechnology and healthcare industries. Treadwell Therapeutics' initiatives and promising pipeline make it an intriguing prospect for venture capital firms seeking opportunities in the biotech sector.